NCT07680530已完成不适用
SpO2 Verification Study - Philips Nasal Alar With Nellcor OxiMax SpO2 Board (453564624031)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
研究概览
简要总结
The primary purpose of the clinical investigation is to verify the SpO2 accuracy of the Philips AlarX5 SpO2 sensor with Nellcor OxiMax SpO2 Board.
详细描述
To verify the SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) with the Nellcor OxiMax pulse oximetry technology during non-motion conditions over the range of 70-100% SaO2, when compared with the reference SaO2 obtained from CO-Oximetry analysis of arterial blood samples.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant must have the ability to understand and provide written informed consent
- •Participant is an adult between 18-50 years of age
- •Participant must be willing and able to comply with study procedures and duration
- •Participant is a non-smoker or who has not smoked within 2 days prior to the study
排除标准
- •Participant is considered as being morbidly obese (defined as BMI >39.5)
- •Compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, hands, nose, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos (e.g. permanent, Henna) or artificial dyes (e.g. spray tan, artificial tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
- •Females who are pregnant
- •Females who are trying to get pregnant with confirmation of positive urine pregnancy test
- •Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)
- •Participants with known respiratory conditions such as: (self-reported)
- •uncontrolled / severe asthma
- •pneumonia / bronchitis
- •shortness of breath / respiratory distress
- •unresolved respiratory or lung surgery
- •emphysema, COPD, lung disease
- •recent COVID with hospitalization
- •Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)
- •high blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings (reviewed during health screen)
- •have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)
- •chest pain (angina)
- •heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
- •previous heart attack
- •blocked artery
- •unexplained shortness of breath
- •congestive heart failure (CHF)
- •history of stroke
- •transient ischemic attack
- •carotid artery disease
- •myocardial ischemia
- •myocardial infarction
- •cardiomyopathy
- •implantable active medical device such as pacemaker or automatic defibrillator
- •Participants with self-reported health conditions
- •uncontrolled thyroid disease
- •kidney disease / chronic renal impairment,
- •history of seizures (except childhood febrile seizures)
- •history of unexplained syncope
- •recent history of frequent migraine headaches
- •recent symptomatic head injury (within the last 2 months) with continued symptoms
- •cancer requiring chemotherapy, radiation, or current treatment - Participants with known clotting disorders (self reported)
- •history of bleeding disorders or personal history of prolonged bleeding from injury
- •history of blood clots
- •hemophilia
- •current use of blood thinner: prescription or daily use of aspirin
- •Sickle Cell Trait or Disease - Participants with self-reported dermatological conditions at sensor application sites
- •severe dermatitis
- •hyperkeratosis
- •nail fungus - Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self reported)
- •Participants with severe allergies to iodine (only applicable if iodine is used)
- •Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
- •Participants with allergies to ultrasound gel
- •Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio <0.4)
- •Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits.
- •Unwillingness or inability to remove makeup, creams, lotions, sunscreen, or powders from application sites on the nose or ear.
- 另有 5 项未显示
研究组 & 干预措施
Healthy Volunteers
Participants are healthy, non-smoking (or has refrained from smoking for 2 days) competent adults, ages 18 to 50 years.
干预措施: Evaluation of Oxygen Sensors (Other)
结局指标
主要结局
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
时间窗: Up to 6 weeks
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
次要结局
- Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (earlobe placement) during non-motion conditions.(Up to 6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
NEXT GEN - PHILIPS OPTIMUSPulse OximetryNCT07521735Philips Clinical & Medical Affairs Global46
已完成
不适用
SPO2 VALIDATION STUDY - PHILIPS FAST 2025NCT07221526Philips Clinical & Medical Affairs Global86
招募中
不适用
Evaluation of the Reliability of AAR as an Independent Tool for Surgical Indication in Nasal ObstructionNCT07379775Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer200
尚未招募
不适用
SpO2 Infant and Pediatric StudyNCT07615738GE Healthcare180
尚未招募
不适用
Use of analysis of blood oxygen saturation level for the diagnosis of obstructive sleep apnea and its relation with heart disease risk in Indian subjectsCTRI/2025/10/096169Dr Saurabh Mittal200